Clinical Trials | CATALINA-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women with Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6
CATALINA-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6
The University of Virginia is looking for women aged 18 and older to take part in a clinical trial. You may be eligible to participate if you have recurrent platinum resistant advanced or metastatic high grade serous ovarian, primary peritoneal, or fallopian tube cancer. The goal of this study is to see how well a medication called TORL-1-23 works in treating platinum-resistant ovarian, primary peritoneal, or fallopian tube cancers that have high levels of a protein called CLDN6. If you participate in this study, you may receive the study drug called TORL-1-23 intravenously. This study will include: blood draws, electrocardiograms (ECGs), eye exams, imaging assessments, questionnaires, and physical examinations. Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance. More information can be found here: https://clinicaltrials.gov/study/NCT06690775